
The evolving topic of tattoos in cancer epidemiology and why studies should be prospective.

Dr. Milena Foerster Environment and Lifestyle Epidemiology Branch

foersterm@iarc.fr

International Agency for Research on Cancer








- 1. What is known so far
- 2. Tattoos in (cancer) epidemiology
- 4. Cross-sectional vs prospective design
- 5. Outlook

What is known so far

- Carcinogens found in tattoo inks (pigments or contaminants)
- Classification of these substances related (mostly) to respiratory or oral exposure
- Most tattoo pigments do not stay in the skin
- Cancer sites of interest : Lymphatic (NHLs) and skin
- Multiple possible "exposure routes" to cancer formation
- High relevance of the research question
- -> Need for well-designed epidemiological studies to assess potential health risks
 - Two small case control studies on tattoos and skin and lymphatic cancer published ambiguous results (Barton et al. (2020), Warner et al. (2020))
 - Larger case-control study ongoing (Lund University, Sweden)





Tattoos in (cancer) epidemiology Data sources

- 1. Population cohorts:
- Large samples representative of the general population and typically followed-up during xx years/lifetime
- Collect and update vast sociodemographic, lifestyle, and medical data
- Consists of exposed and non-exposed individuals
- Open to external research upon reasonable request
- 2. Independent data collection via questionnaire / online
- Useful for specific questions e.g. tattoos, COVID
- Risky if used as only data source
- 3. "Objective" data sources / registry data:
- To retrieve medical history and mortality data
- Open to external research upon reasonable request




Tattoos in (cancer) epidemiology Study designs






Relevant factors:

Population prevalence



Relevant fators:


Population prevalence



Relevant factors:

Population prevalence

Exposure change over time



Relevant factors:


Population prevalence

Exposure change over time

Exposure-response relationship

- High/low exposed populations
- Life-time vs one-time exposure
- Cumulative vs threshold exposure

Tattoos in (cancer) epidemiology



Relevant factors:

Incidence

Outcome **Retrospective exposure** Non-melanoma SC assessment Melanoma NHLs N cancer cases/ 100 000 20 1200 % tattooed 900 10 600 Carlos and 300 ~2 2010 exposed 2020 2000 2030 2040 20 years lag time 10 years lag time

Relevant factors:


Incidence

Lagtime


Dr. Milena Foerster - 2nd International Conference on Tattoo Safety, BfR, Berlin

Tattoos in (cancer) epidemiology


Tattoos in (cancer) epidemiology Outcome



Tattoos in (cancer) epidemiology Outcome



Dr. Milena Foerster - 2nd International Conference on Tattoo Safety, BfR, Berlin




Dr. Milena Foerster - 2nd International Conference on Tattoo Safety, BfR, Berlin

CASE CONTROL STUDY

- Outcome and exposure assessed crosssectional or retrospectively
 - + Allows for rapid data analysis
- Exposure assessed today cannot account for
 low population exposure >10 years ago (lagtime cannot be taken into account)
- Outcome assessed today cannot account for high mortality of cancer cases

- Cases recruited today unrepresentative (coexposed, too old) In most instances case control studies can give a first idea about a given association.

In the case of tattoos this is not necessarily the case



PROSPECTIVE STUDY


Cases recruited prospectively from T0, exposure assessed at T0 (and if possible at T0+X)

+ Assures information on outcome and exposure for ALL potential cases (no mortality bias)

+ Accounts for the rising population exposure

+Different lagtimes can be assumed and tested

- Exposure assessed only once today cannot account for tattoos tomorrow
- Needs a sufficient large N for each outcome: long waiting time for results



Outlook

+ Prospective assessment of tattoo exposure in the French and German national cohorts Constances and NAKO

- + data on relevant sociodemographic factors & confounder data etc available, annual follow-up
- + cases and controls in one cohort

Protocol

1. Send out a tattoo exposure questionnaire (EpiTAT) to all tattooed cohort members in 2022 (approx. 14,000 tattooed people in France & 15,000 in Germany)

2. Prospective recruitment of cancer cases via national health insurance data (France) and cancer registries (Germany)

Ongoing

+ Validation study of EpiTAT in ~100 tattooed individuals





Thank you !

ENV Branch at IARC: Joachim Schüz, Lucas Dufour, Isabelle Deltour, Monika Moissoinier, Valerie McCormack, Liacine Bouaoun

The ESTP, and in particularly lnes and Wolfgang

Constances: Prof. Marie Zins, Prof. Marcel Goldberg

Universite Paris-Est Creteil: Prof. Khaled Ezzedine

DKFZ: Dr. Lena Koch-Gallenkamp, Prof. Hermann Brenner

Saarland cancer registry: Dr. Holleczek

All participating NAKO study centres

Contact: foersterm@iarc. fr

> International Agency for Research on Cancer

